Related Experiment Videos
Recurrence of duodenal ulcer after medical treatment
Insights
Long-term follow-up of duodenal ulcer treatments showed similar relapse rates for cimetidine, ranitidine, and pirenzepine. Tripotassium dicitrato-bismuthate offered short-term benefits, while smoking increased relapse risk.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Duodenal ulcers are common gastrointestinal conditions.
- Effective management strategies are crucial for preventing relapse.
- Previous studies evaluated various pharmacological interventions.
Purpose of the Study:
- To assess the long-term efficacy of different duodenal ulcer treatments.
- To compare relapse rates among cimetidine, ranitidine, pirenzepine, tripotassium dicitrato-bismuthate, and placebo groups.
- To investigate the influence of smoking on ulcer recurrence.
Main Methods:
- Long-term endoscopic follow-up of 562 patients with healed duodenal ulcers.
- Double-blind controlled trials comparing multiple medical treatments.
- Follow-up duration of up to four years or until relapse.
- Analysis of relapse rates based on treatment group and smoking status.
Main Results:
- No significant difference in relapse rates was observed between cimetidine, ranitidine, pirenzepine, and placebo groups.
- Tripotassium dicitrato-bismuthate demonstrated a significant advantage at six and twelve months post-treatment, but not thereafter.
- Smokers consistently exhibited higher duodenal ulcer relapse rates compared to non-smokers across all treatment arms.
Conclusions:
- Cimetidine, ranitidine, and pirenzepine show comparable long-term effectiveness in preventing duodenal ulcer relapse.
- Tripotassium dicitrato-bismuthate may offer short-term benefits, but its long-term advantage is not sustained.
- Smoking cessation is an important factor in managing duodenal ulcer recurrence.
Abstract:
562 patients whose duodenal ulcers had healed in a series of double-blind controlled trials of various medical treatments were enrolled in a long-term endoscopic follow-up. 436 were followed for up to four years or until relapse. Relapse rates did not differ between the groups treated with cimetidine, ranitidine, pirenzepine, or placebo. At six and twelve months but not subsequently, there was a significant advantage for tripotassium dicitrato-bismuthate. Relapse rates were at all times higher in smokers than in non-smokers.